Os 389 melhores médicos do mundo para o tratamento de cancro do esófago

O Dr. Yaacov Lawrence é o Chefe de Oncologia Radioterápica no Centro Médico Sheba. Ele é especializado em radioterapia de precisão e neuro-oncologia. O Dr. Lawrence foi pioneiro na radiocirurgia do plexo celíaco para o controle da dor no câncer de pâncreas. Ele possui a designação FASTRO, uma das mais altas honrarias em sua especialidade.

• Lidera o Programa de Câncer Gastrointestinal no Centro Médico Sheba.
• Realiza radiocirurgia estereotática para tumores cerebrais e cânceres do sistema nervoso.
• Autor de mais de 280 publicações científicas sobre protocolos de radiação personalizados.
• Concluiu o treinamento de fellowship em oncologia radioterápica na Universidade Thomas Jefferson.

O Dr. Raanan Berger é o diretor do Centro de Câncer do Sheba Medical Center. Ele foi incluído na lista de "Melhores Médicos" da Forbes Israel em 2025. O Dr. Berger é especializado em oncologia geniturinária e trata tumores complexos de próstata com radioterapia. Ele completou um pós-doutorado no Dana-Farber/Harvard Cancer Institute.

• Chefia a unidade de pesquisa clínica focada em oncologia molecular.
• Coautor de mais de 20 artigos revisados por pares sobre câncer de próstata e mutações BRCA.
• Membro da Sociedade Americana de Oncologia Clínica (ASCO).
• Realiza terapia sistêmica e radioterapia em um hospital classificado entre os 10 melhores do mundo.

O Dr. Beni Boursi é um oncologista de destaque no Sheba Medical Center. Fundou o Grupo de Trabalho sobre Microbioma da ECOG-ACRIN. Especializa-se no tratamento de cancros gastrointestinais utilizando modulação microbiana inovadora. O Dr. Boursi é certificado em medicina interna e oncologia médica. Obteve o seu diploma de medicina com as mais altas distinções na Universidade de Tel Aviv.

• Concluiu estágios em oncologia na Universidade da Pensilvânia.
• Formou-se em oncologia médica no MD Anderson e na Mayo Clinic.
• Desenvolveu modelos preditivos para o diagnóstico precoce do cancro colorretal e pancreático.
• Publicou pesquisas sobre microbioma em oncologia na prestigiada revista Science.

O Prof. Keun Chil Park, MD, chefia a Divisão de Hematologia-Oncologia no Samsung Medical Center com um forte foco em câncer de esôfago.

• Interesses especiais em câncer de pulmão, cabeça e pescoço, e esôfago
• Membro de múltiplas associações oncológicas de prestígio, incluindo ASCO e ESMO
• Graduado pela Faculdade de Medicina da Universidade Nacional de Seul

O Dr. Choi Yong Soo é cirurgião torácico no Samsung Medical Center, especializado em tratamentos de câncer de esôfago.

• Especialista em intervenções cirúrgicas para casos complexos de câncer de esôfago
• Trabalha em uma das principais instituições médicas da Coreia do Sul
• Foca no fornecimento de planos de tratamento personalizados

Subchefe do Departamento de Oncologia do Centro Médico Rambam – especializado em casos complexos de câncer de esôfago.

• Ampla experiência em oncologia com foco em câncer de esôfago
• Trabalha em um centro médico líder em Israel
• Lida tanto com o diagnóstico quanto com o planejamento do tratamento

O Dr. Alexander Beny lidera o Serviço de Malignidade Gastrointestinal no Rambam Medical Center, especializando-se em cancro do esófago.

• Certificado em Oncologia Médica e Radioterapia
• Chefiou vários departamentos de oncologia, incluindo o Hospital Geral Italiano
• Formado em técnicas modernas de braquiterapia pela ESTRO
• Certificado pelo Conselho da Comunidade Europeia em Medicina

O Professor Jablonski-Perec formou-se no renomado Sloan-Kettering Cancer Center – trazendo especialização de classe mundial em cancro do esôfago para o Hadassah Medical Center.

• Chefiar o Instituto de Oncologia do Hadassah
• Ser professor no Departamento de Oncologia da Universidade Hebraica
• Ser membro de comunidades internacionais de pesquisa em cancro
• Ser beneficiário de uma bolsa da Faculdade de Medicina do Hadassah

Radioterapeuta especializado no tratamento do cancro do esófago no Centro Médico Assuta.

• Foca-se em técnicas precisas de radioterapia
• Trabalha com equipas multidisciplinares para um cuidado abrangente
• Utiliza imagiologia avançada para tratamento direcionado

Mais de 15.000 procedimentos cirúrgicos realizados – O Dr. de Lacy é um pioneiro em técnicas minimamente invasivas para o cancro do esófago no Hospital Quiron Barcelona.

• Realiza mais de 1.000 intervenções anualmente utilizando métodos laparoscópicos e robóticos
• Presidente da Associação Europeia de Cirurgiões-Endoscopistas
• Pioneiro de renome mundial em técnicas de cirurgia gastrointestinal
• Conferencista sobre laparoscopia avançada e técnicas cirúrgicas

Com 38 anos de experiência, o Prof. Reni especializa-se em cancros gastroesofágicos no San Raffaele e lidera a investigação sobre o cancro do pâncreas.

• Coordena as diretrizes da AIOM para o tratamento do cancro do pâncreas
• Publicou mais de 180 artigos sobre terapias oncológicas
• Diretor do Centro de Pâncreas no San Raffaele
• Conduz ensaios clínicos para o cancro do pâncreas metastático

O médico é especialista em cirurgia geral com foco em doenças da tireoide e paratireoide, realizando mais de 200 cirurgias anualmente usando técnicas minimamente invasivas. Além disso, o médico é habilidoso no tratamento laparoscópico de doenças adrenais. O médico aplica ampla experiência na organização do tratamento de patologias gastrointestinais, incluindo esôfago, estômago, cólon, fígado, ductos biliares e pâncreas, bem como no tratamento de doenças da parede abdominal e doenças tumorais complexas.<\/p>

O Dr. Erkan Göcen é especialista em Oncologia Radioterápica no Hospital Privado Çerkezköy Optimed (Optimed Health Group). Formou-se na Universidade de Istambul, Faculdade de Medicina (Çapa), em 2003.

Carreira: Treinou e praticou em Oncologia Radioterápica de 2010 a 2012. Trabalhou em instituições de saúde públicas e privadas de 2012 a 2016. Trabalhou no setor médico privado como especialista em Oncologia Radioterápica de 2016 a 2023. Está no Hospital Optimed desde 2024.

Interesses clínicos: cânceres de cérebro, cabeça e pescoço, esôfago, estômago, colorretal, pâncreas, próstata, bexiga, pulmão, tecidos moles (sarcomas), pele, útero e colo do útero, e mama. Afiliações: Sociedade Turca de Oncologia Radioterápica (TROD) e Câmara Médica de Tekirdağ. Idiomas: inglês e turco.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Armando Chiari é fundador da Clínica Armando Chiari, em Belo Horizonte. Desenvolveu a técnica de blefaroplastia estendida, que trata a região das pálpebras e o posicionamento das sobrancelhas por meio de uma única incisão. É chefe do Departamento de Cirurgia Plástica da UFMG.

• Ensinou sua técnica de mamoplastia em L em encontros de cirurgia no Brasil e no México.
• Realiza mastopexia mamária, redução mamária e redução complexa de implantes.
• Publicou resultados de cirurgias periorbitais na Revista Brasileira de Cirurgia Plástica.
• Realiza miniabdominoplastia e cirurgia de implante glúteo.

O Dr. Gustavo Pereira Filho realizou mais de 5.000 cirurgias plásticas em sua clínica em Porto Alegre. Realiza procedimentos de rejuvenescimento facial, contorno corporal e cirurgia mamária. O Dr. Filho tem mestrado em Cirurgia e Patologia de Enxertos e é instrutor no Instituto LipoMd.

• Utiliza Renuvion e tecnologia de laser de CO2 para retração da pele e produção de colágeno.
• Realiza lipoescultura de média definição, combinando lipoaspiração assistida a vácuo com enxertia de gordura.
• Membro da Sociedade Brasileira de Cirurgia Plástica e da Sociedade Americana de Cirurgiões Plásticos (ASPS).
• Publicou 10 artigos científicos em periódicos de cirurgia plástica.